

No. 35026/117/2021-MD  
Government of India  
Ministry of Chemicals & Fertilizers  
Department of Pharmaceuticals

\*\*\*\*

Janpath Bhawan, New Delhi  
Dated the 2<sup>nd</sup> May, 2022

**OFFICE MEMORANDUM**

**Subject: DoP's OM dated 06.04.2022 – Claims of Local Manufacturers of drugs referred to the Committee of DoP – pending verification, the procurement agencies to exercise their due diligence on the claims of the local manufacturers while proceeding for the procurement- reg.**

The undersigned is directed to inform that based on the requests received from the central procuring entities, where difficulties are being faced in procurement due to non-availability of Class I or Class II suppliers as per the PPO Order, a list of 213 drugs (actually these were 209 drugs) was published on the Department of Pharmaceuticals (DoP) website vide Public Notice dated **28.02.2022**, seeking details of the local manufacturers available for these Drugs by **15.03.2022**. In response, for 67 drugs, the domestic manufacturers have submitted their details as manufacturers of these drugs and for 142 drugs, no local manufacturer has claimed as manufacturing in India.

2. It is directed to refer to the Department of Pharmaceuticals OM No. 35026/117/2021-MD dated 06.04.2022 wherein the Department has shared, with the administrative departments of central procuring entities, the details of Local Manufacturers of **67** Drugs vide OM dated **06.04.2022** in order to assist them in the procurement of the few of the drugs shared by them with DoP,.

3. It is further to inform that as the nodal department for Pharmaceutical and Medical Devices sectors w.r.t PPP-MII Order 2017, the Department of Pharmaceuticals (DoP) had issued guidelines dated 30.12.2020 for implementation of the Order related to procurement of goods and services in Pharmaceuticals Sector (copy enclosed). As per this, the following Committee was constituted for random verification of self-declarations and auditor's / accountant's certificate on random basis and in the case of complaints;

- i. MD, KAPL as Chairman
- ii. Representative from NIPER Ahmedabad as member
- iii. Representative from NPPA as member
- iv. Representative from CDSCO as member
- v. Joint Director (Pricing), DoP as member.

4. Accordingly, the claims of the local manufacturers along with the other details are being referred to the above Committee constituted by the DoP to verify the claims of the local manufacturers of all the 60 drugs (after removing repetitions in the list of 67 drugs).

5. Pending verification of the claims by the Committee, the procurement agencies may exercise their due diligence on the claims of the local manufacturers while proceeding for the procurement, if any urgency is involved in the procurement of these drugs. It is reiterated that it is for the procurement agencies to examine the license and other statutory compliance by the companies if and when they bid under the tender floated for public procurement.

6. This issues with the approval of the Competent Authority. This OM accordingly, follows up the DoP's OM No. No. 35026/117/2021-MD dated 06.04.2022.



(Arvind Kumar)

Under Secretary to the Govt. of India

Email: arvind.76@gov.in

Tele: 011-23352298

To

1. Secretary, Ministry of Health & Family Welfare.
2. Secretary, Ministry of Defence.
3. Secretary, Ministry of Labour and Employment
4. Chairman, Railway Board, Ministry of Railway
5. Other Central Procurement Agencies adopting PPP-MII Order

Copy for information to

1. PPS to Secretary, DoP / Secretary, DPIIT.